击败Xkr8可以通过调节瘤免疫微环境来提高化疗疗效
Yuang Chen1, Chien-Yu Chen1, Haozhe Huang1
1Center for Pharmacogenetics, Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
用化疗准Xkr8可以增强抗瘤免疫力,克服抗药性. 在胰腺瘤中,Xkr8 Knockdown促进免疫细胞死亡和有利的T细胞分化.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 斯克兰布酶Xkr8调节了类胺 (PS) 在亡过程中的外部化,有助于瘤免疫抑制.
- 用化疗准Xkr8提供了一种增强抗瘤免疫反应和克服化疗耐药性的策略.
研究的目的:
- 在一个相关的 ортотоп瘤模型中,评估结合Xkr8敲击和化疗的疗效.
- 使用单细胞RNA测序 (scRNA-seq) 阐明底层机制.
主要方法:
- 利用一个正确的胰腺瘤模型.
- 采用了Xkr8小干扰RNA (siRNA) 和化疗前药FuOXP.
- 进行了深入的单细胞RNA测序 (scRNA-seq) 和单细胞轨迹分析.
主要成果:
- 通过阻碍细胞亡清除,Xkr8敲击诱导免疫细胞死亡 (ICD).
- 组合疗法在 ортотоп性胰腺瘤中显示出显著的治疗效果.
- 观察到瘤微环境 (TME) 中增殖NK细胞和激活巨细胞的透增加.
- 单细胞轨迹分析揭示了瘤透的CD8+T细胞向细胞毒性表型的转变.
结论:
- 与化疗相结合的Xkr8敲击显示了癌症治疗的前景.
- 这种策略调节瘤微环境 (TME),以增强抗瘤免疫力.
- 这些发现支持在各种癌症类型中将Xkr8抑制与化疗相结合的理由.
更多相关视频
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
10:59Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment
Published on: November 23, 2017
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
The Tumor Microenvironment
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
